- +86 1872918458
- maggie@sinotcell.com
- High-tech Zone,Xi’an, Shaanxi, China
Hematologic malignancies are a type of malignant tumor originating from the hematopoietic system, including leukemia, lymphoma, and multiple myeloma, etc.CAR-T cell therapy, as an innovative immunotherapy, has already demonstrated outstanding efficacy in the treatment of relapsed/refractory hematologic malignancies.
Hematologic malignancies are a type of malignant tumor originating from the hematopoietic system or the lymphatic system, including leukemia, lymphoma, and multiple myeloma, etc.These diseases were once considered “incurable diseases,” but with the rapid development of medical technology, especially the breakthroughs in CAR-T cell therapy, targeted therapy, and immunotherapy, the survival period and quality of life of patients with hematologic malignancies have already been significantly improved.
Our professional medical team is committed to providing the most advanced diagnostic technologies and personalized treatment plans for hematologic malignancy patients worldwide.By integrating international cutting-edge medical resources, we help patients obtain a precise, efficient, and safe treatment experience.
• Acute lymphoblastic leukemia (ALL): the most common childhood cancer, the remission rate of CAR-T therapy can reach over 90%
• Acute myeloid leukemia (AML): the most common type of acute leukemia in adults
• Chronic lymphocytic leukemia (CLL): a slowly progressing B-cell malignant tumor
• Chronic myeloid leukemia (CML): closely related to the BCR-ABL fusion gene
• Hodgkin lymphoma (HL): characterized by Reed-Sternberg cells, the cure rate is as high as 80–90%
• Non-Hodgkin lymphoma (NHL): includes subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, etc.
• CAR-T therapy for relapsed/refractory DLBCL has a complete remission rate of 40–54%
• A malignant proliferative disease of plasma cells, commonly occurring in middle-aged and elderly populations
• BCMA-targeted CAR-T therapy brings new hope to relapsed/refractory patients
• China independently developed FUCASO® (Equecabtagene Autoleucel) is the world’s first fully human CAR-T product
• Flow cytometry: precisely identifies surface markers of tumor cells
• Genetic testing: FISH and NGS technologies guide precise treatment
• Molecular classification: provides a basis for individualized treatment plans
• Imaging evaluation: PET-CT and MRI comprehensively assess disease staging
Common symptoms include persistent fever, night sweats, unexplained weight loss, enlarged lymph nodes, fatigue and weakness, recurrent infections, bleeding tendency, etc. If these symptoms occur, medical examination should be sought in time.
Diagnostic methods include: routine blood test, bone marrow aspiration biopsy, lymph node biopsy, flow cytometry, cytogenetic analysis, molecular biological testing (such as FISH, PCR), imaging examinations (CT, PET-CT, MRI), etc.
CAR-T therapy is currently mainly applicable to relapsed/refractory B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. A professional doctor is required to evaluate whether the patient meets the treatment conditions.
Many types of hematologic malignancies can achieve long-term remission or even cure. The cure rate of Hodgkin lymphoma exceeds 80%, and the cure rate of childhood ALL can reach over 90%. New treatment methods continuously improve patient prognosis.
The treatment cycle varies according to the disease type and treatment plan. CAR-T therapy takes about 3–4 weeks from cell collection to infusion, and the observation period is about 2–4 weeks.
The cost varies depending on the treatment plan. Receiving CAR-T therapy in China can save 50–70% of the cost compared with European and American countries. We provide transparent cost assessments and multiple payment options.
Understand the treatment indications and evaluation criteria for patients with hematologic malignancies
Explore our medical team, successful cases, and treatment advantages
Understand how CAR-T changes the treatment landscape of hematologic malignancies
24-hour professional consultation to formulate the best treatment plan for you
